The U.S. Food and Drug Administration questioned the value of taking aspirin to try to ward off a first heart attack or stroke in people who have never had cardiovascular problems. The FDA's statement follows its decision last week to turn down a request by German drugmaker Bayer AG to change the labeling on packages in order to market aspirin's value in preventing heart attacks in people who have never had cardiovascular disease. Read the full story